Jagsonpal Pharmaceuticals holds 47th AGM, appoints new independent director
- Jagsonpal Pharmaceuticals held its 47th AGM on September 18, 2026
- Shareholders approved FY26 financial statements and dividend declaration
- Anil Kumar Matai appointed as Independent Director via special resolution
- Prithpal Singh Kochar reappointed as director retiring by rotation
*this image is generated using AI for illustrative purposes only.
Jagsonpal Pharmaceuticals held its 47th Annual General Meeting on September 18, 2026. The meeting concluded with shareholders approving the adoption of audited financial statements for FY26 and declaring a dividend for the period ended March 31, 2026.
The proceedings were conducted via Video Conference/Other Audio Visual Means (VC/OAVM) in compliance with the Companies Act, 2013 and SEBI Listing Regulations. Manish Gupta, Managing Director, chaired the session in the absence of Harsha Raghavan, Non-Executive Director and Chairperson.
Key Resolutions Passed
Shareholders transacted both ordinary and special business items during the meeting. The resolutions included the reappointment of a retiring director and the ratification of cost auditor remuneration.
| Item No. | Resolution Description | Type |
|---|---|---|
| 1 | Adoption of Audited Financial Statements for FY26 | Ordinary |
| 2 | Declaration of Dividend for FY26 | Ordinary |
| 3 | Reappointment of Prithpal Singh Kochar as Director | Ordinary |
| 4 | Ratification of remuneration for Kirit Mehta & CO LLP | Ordinary |
| 5 | Appointment of Anil Kumar Matai as Independent Director | Special |
Prithpal Singh Kochar, who retires by rotation, was eligible and offered himself for reappointment. The company also ratified the remuneration payable to Kirit Mehta & CO LLP, Cost Accountants, for the financial year ending March 31, 2027.
Governance Updates
A significant governance change occurred with the special resolution to appoint Anil Kumar Matai (DIN: 03122685) as an Independent Director. This appointment strengthens the board’s independent oversight capabilities.
Ayush Khandelwal & Associates was appointed as the Scrutinizer for the e-voting process. Remote e-voting commenced on September 14, 2026, and concluded on September 17, 2026. The detailed voting results and Scrutinizer’s Report will be disseminated to stock exchanges and placed on the company’s website within two working days of the meeting’s conclusion.
What the Numbers Show
The source document confirms the procedural completion of shareholder approvals but does not disclose specific financial figures such as revenue, profit, or dividend per share amounts in this filing. The focus remains on corporate governance compliance and director appointments rather than financial performance metrics.
Historical Stock Returns for Jagsonpal Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.52% | -1.96% | -2.19% | +23.42% | -6.02% | +253.59% |
How might the appointment of Anil Kumar Matai as an Independent Director influence Jagsonpal's strategic decision-making and regulatory compliance in the upcoming fiscal year?
Given the absence of specific financial metrics in this filing, what are the market's expectations for Jagsonpal's FY26 revenue growth and profitability based on recent sector trends?
What is the likely impact of the declared dividend on shareholder returns compared to previous years, and does it signal management's confidence in future cash flows?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
